Increased complexity in carcinomas: Analyzing and modeling the interaction of human cancer cells with their microenvironment

Seminars in Cancer Biology

Volumn 35, Issue , 2015, Pages 107-124

  Stadler, Mira ^a   Walter, Stefanie ^a   Walzl, Angelika ^a   Kramer, Nina ^a   Unger, Christine ^a   Scherzer, Martin ^a,b   Unterleuthner, Daniela ^a,c   Hengstschläger, Markus ^a   Krupitza, Georg ^a   Dolznig, Helmut ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b KAROLINSKA INSTITUTE   (Sweden)

^c UNIVERSITY OF VETERINARY MEDICINE   (Austria)

Author keywords

3D; Cancer heterogeneity; Drug development; Spheroid; Tumor stroma

Indexed keywords

CANCER CELL; CANCER CELL ORGANOID MODEL; CANCER MODEL; CANCER TISSUE ORIGINATED SPHEROID; CARCINOGENESIS; CARCINOMA; CELL HETEROGENEITY; CELL SEPARATION; DISEASE ACTIVITY; DISEASE MODEL; HETEROTYPIC MULTICELLULAR TUMOR SPHEROID; HISTOLOGY; HUMAN; IN VITRO STUDY; IN VIVO STUDY; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; MOLECULAR DYNAMICS; MOLECULAR INTERACTION; MOLECULAR PATHOLOGY; MULTICELLULAR TUMOR SPHEROID; NONHUMAN; ONCOLOGICAL PROCEDURE; ORGANOTYPIC MULTICELLULAR SPHEROID; PREDICTION; QUANTITATIVE ANALYSIS; REVIEW; TISSUE METABOLISM; TISSUE SCAFFOLD; TUMOR SPHEROID; TUMOROSPHERE; ANIMAL; BIOLOGICAL MODEL; CELL COMMUNICATION; FIBROBLAST; GENETICS; METABOLISM; MULTICELLULAR SPHEROID; PATHOLOGY; STROMA CELL; TISSUE CULTURE TECHNIQUE; TUMOR CELL CULTURE; TUMOR MICROENVIRONMENT;

ANIMALS; CARCINOMA; CELL COMMUNICATION; DISEASE MODELS, ANIMAL; FIBROBLASTS; HUMANS; MODELS, BIOLOGICAL; SPHEROIDS, CELLULAR; STROMAL CELLS; TISSUE CULTURE TECHNIQUES; TUMOR CELLS, CULTURED; TUMOR MICROENVIRONMENT;

EID: 84948720706     PISSN: 1044579X     EISSN: 10963650     Source Type: Journal    
DOI: 10.1016/j.semcancer.2015.08.007     Document Type: Review

References (249)

1. Choi S.J., Kim H.S., Ahn S.J., Jeong Y.M., Choi H.Y. Evaluation of the growth pattern of carcinoma of colon and rectum by MDCT. Acta Radiol. 2013, 54(5):487-492.
2. Bergers G., Brekken R., McMahon G., Vu T.H., Itoh T., Tamaki K., et al. Matrix metalloproteinase-9 triggers the angiogenic switch during carcinogenesis. Nat. Cell Biol. 2000, 2(10):737-744.
3. Bergers G., Benjamin L.E. Tumorigenesis and the angiogenic switch. Nat. Rev. Cancer 2003, 3(6):401-410.
4. Hirai H., Samokhvalov I.M., Fujimoto T., Nishikawa S., Imanishi J., Nishikawa S. Involvement of Runx1 in the down-regulation of fetal liver kinase-1 expression during transition of endothelial cells to hematopoietic cells. Blood 2005, 106(6):1948-1955.
5. Chen M.J., Yokomizo T., Zeigler B.M., Dzierzak E., Speck N.A. Runx1 is required for the endothelial to haematopoietic cell transition but not thereafter. Nature 2009, 457(7231):887-891.
6. Butler J.M., Kobayashi H., Rafii S. Instructive role of the vascular niche in promoting tumour growth and tissue repair by angiocrine factors. Nat. Rev. Cancer 2010, 10(2):138-146.
7. Karnoub A.E., Dash A.B., Vo A.P., Sullivan A., Brooks M.W., Bell G.W., et al. Mesenchymal stem cells within tumour stroma promote breast cancer metastasis. Nature 2007, 449(7162):557-563.
8. Yagi H., Kitagawa Y. The role of mesenchymal stem cells in cancer development. Front. Genet. 2013, 4:261.
9. De Vlieghere E., Verset L., Demetter P., Bracke M., De Wever O. Cancer-associated fibroblasts as target and tool in cancer therapeutics and diagnostics. Virchows Arch. 2015.
10. Nguyen L.V., Vanner R., Dirks P., Eaves C.J. Cancer stem cells: an evolving concept. Nat. Rev. Cancer 2012, 12(2):133-143.
11. Pribluda A., de la Cruz C.C., Jackson E.L. Intratumoral heterogeneity: from diversity comes resistance. Clin. Cancer Res. 2015, 21(13):2916-2923.
12. Brabletz T., Jung A., Reu S., Porzner M., Hlubek F., Kunz-Schughart L.A., et al. Variable betacatenin expression in colorectal cancers indicates tumor progression driven by the tumor environment. Proc. Natl. Acad. Sci. U.S.A. 2001, 98(18):10356-10361.
13. Lamouille S., Xu J., Derynck R. Molecular mechanisms of epithelial-mesenchymal transition. Nat. Rev. Mol. Cell Biol. 2014, 15(3):178-196.
14. Pattabiraman D.R., Weinberg R.A. Tackling the cancer stem cells - what challenges do they pose?. Nat. Rev. Drug Discov. 2014, 13(7):497-512.
15. Mani S.A., Guo W., Liao M.J., Eaton E.N., Ayyanan A., Zhou A.Y., et al. The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell 2008, 133(4):704-715.
16. Thiery J.P., Acloque H., Huang R.Y., Nieto M.A. Epithelial-mesenchymal transitions in development and disease. Cell 2009, 139(5):871-890.
17. Brabletz T. To differentiate or not - routes towards metastasis. Nat. Rev. Cancer 2012, 12(6):425-436.
18. Saunders N.A., Simpson F., Thompson E.W., Hill M.M., Endo-Munoz L., Leggatt G., et al. Role of intratumoural heterogeneity in cancer drug resistance: molecular and clinical perspectives. EMBO Mol. Med. 2012, 4(8):675-684.
19. Burrell R.A., McGranahan N., Bartek J., Swanton C. The causes and consequences of genetic heterogeneity in cancer evolution. Nature 2013, 501(7467):338-345.
20. Warburg O. On the origin of cancer cells. Science 1956, 123(3191):309-314.
21. Mullard A. 2013 in reflection. Nat. Rev. Drug Discov. 2014, 13(1):5-7.
22. Cook N., Jodrell D.I., Tuveson D.A. Predictive in vivo animal models and translation to clinical trials. Drug Discov. Today 2012, 17(5-6):253-260.
23. Pietras K., Ostman A. Hallmarks of cancer: interactions with the tumor stroma. Exp. Cell Res. 2010, 316(8):1324-1331.
24. Scannell J.W., Blanckley A., Boldon H., Warrington B. Diagnosing the decline in pharmaceutical R&D efficiency. Nat. Rev. Drug Discov. 2012, 11(3):191-200.
25. Arrowsmith J., Miller P. Trial watch: phase II and phase III attrition rates 2011-2012. Nat. Rev. Drug Discov. 2013, 12(8):569.
26. Kola I., Landis J. Can the pharmaceutical industry reduce attrition rates?. Nat. Rev. Drug Discov. 2004, 3(8):711-715.
27. Coons A.H., Creech H.J., Jones R.N., Berliner E. The demonstration of pneumococcal antigen in tissues by the use of fluorescent antibody. J. Immunol. 1942, 45(3):159-170.
28. Ramos-Vara J.A., Miller M.A. When tissue antigens and antibodies get along: revisiting the technical aspects of immunohistochemistry - the red, brown, and blue technique. Vet. Pathol. 2014, 51(1):42-87.
29. Rudiger T., Hofler H., Kreipe H.H., Nizze H., Pfeifer U., Stein H., et al. Quality assurance in immunohistochemistry: results of an interlaboratory trial involving 172 pathologists. Am. J. Surg. Pathol. 2002, 26(7):873-882.
30. Walker R.A. Quantification of immunohistochemistry - issues concerning methods, utility and semiquantitative assessment I. Histopathology 2006, 49(4):406-410.
31. Taylor C.R., Levenson R.M. Quantification of immunohistochemistry - issues concerning methods, utility and semiquantitative assessment II. Histopathology 2006, 49(4):411-424.
32. Warren M.V., Chan W.Y., Ridley J.M. Analysis of protein biomarkers in human clinical tumor samples: critical aspects to success from tissue acquisition to analysis. Biomark. Med. 2011, 5(2):227-248.
33. Schindelin J., Arganda-Carreras I., Frise E., Kaynig V., Longair M., Pietzsch T., et al. Fiji: an open-source platform for biological-image analysis. Nat. Methods 2012, 9(7):676-682.
34. Doyle S., Feldman M., Tomaszewski J., Madabhushi A. A boosted Bayesian multiresolution classifier for prostate cancer detection from digitized needle biopsies. IEEE Trans. Biomed. Eng. 2012, 59(5):1205-1218.
35. Khan M.S., Luong T.V., Watkins J., Toumpanakis C., Caplin M.E., Meyer T. A comparison of Ki-67 and mitotic count as prognostic markers for metastatic pancreatic and midgut neuroendocrine neoplasms. Br. J. Cancer 2013, 108(9):1838-1845.
36. Beck A.H., Sangoi A.R., Leung S., Marinelli R.J., Nielsen T.O., van de Vijver M.J., et al. Systematic analysis of breast cancer morphology uncovers stromal features associated with survival. Sci. Transl. Med. 2011, 3(108):108ra13.
37. Schlederer M., Mueller K.M., Haybaeck J., Heider S., Huttary N., Rosner M., et al. Reliable quantification of protein expression and cellular localization in histological sections. PLOS ONE 2014, 9(7):e100822.
38. Heindl A., Nawaz S., Yuan Y. Mapping spatial heterogeneity in the tumor microenvironment: a new era for digital pathology. Lab. Invest. 2015, 95(4):377-384.
39. Koos B., Kamali-Moghaddam M., David L., Sobrinho-Simoes M., Dimberg A., Nilsson M., et al. Next-generation pathology - surveillance of tumor microecology. J. Mol. Biol. 2015, 427(11):2013-2022.
40. Simone N.L., Bonner R.F., Gillespie J.W., Emmert-Buck M.R., Liotta L.A. Laser-capture microdissection: opening the microscopic frontier to molecular analysis. Trends Genet. 1998, 14(7):272-276.
41. Rupp C., Dolznig H., Puri C., Schweifer N., Sommergruber W., Kraut N., et al. Laser capture microdissection of epithelial cancers guided by antibodies against fibroblast activation protein and endosialin. Diagn. Mol. Pathol. 2006, 15(1):35-42.
42. Rupp C., Scherzer M., Rudisch A., Unger C., Haslinger C., Schweifer N., et al. IGFBP7, a novel tumor stroma marker, with growth-promoting effects in colon cancer through a paracrine tumor-stroma interaction. Oncogene 2014, 34(7):815-825.
43. Datta S., Malhotra L., Dickerson R., Chaffee S., Sen C.K., Roy S. Laser capture microdissection: big data from small samples. Histol. Histopathol. 2015, 11622.
44. Espina V., Wulfkuhle J.D., Calvert V.S., VanMeter A., Zhou W., Coukos G., et al. Laser-capture microdissection. Nat. Protoc. 2006, 1(2):586-603.
45. Esposito G. Complementary techniques: laser capture microdissection - increasing specificity of gene expression profiling of cancer specimens. Adv. Exp. Med. Biol. 2007, 593:54-65.
46. Rupp C., Dolznig H., Puri C., Sommergruber W., Kerjaschki D., Rettig W.J., et al. Mouse endosialin, a C-type lectin-like cell surface receptor: expression during embryonic development and induction in experimental cancer neoangiogenesis. Cancer Immun. 2006, 6:10.
47. Nishida N., Nagahara M., Sato T., Mimori K., Sudo T., Tanaka F., et al. Microarray analysis of colorectal cancer stromal tissue reveals upregulation of two oncogenic miRNA clusters. Clin. Cancer Res. 2012, 18(11):3054-3070.
48. Huang C., Yang L., Li Z., Yang J., Zhao J., Dehui X., et al. Detection of CCND1 amplification using laser capture microdissection coupled with real-time polymerase chain reaction in human esophageal squamous cell carcinoma. Cancer Genet. Cytogenet. 2007, 175(1):19-25.
49. Jensen L.H., Cruger D.G., Lindebjerg J., Byriel L., Bruun-Petersen G., Jakobsen A. Laser microdissection and microsatellite analysis of colorectal adenocarcinomas. Anticancer Res. 2006, 26(3A):2069-2074.
50. Bonner R.F., Emmert-Buck M., Cole K., Pohida T., Chuaqui R., Goldstein S., et al. Laser capture microdissection: molecular analysis of tissue. Science 1997, 278(5342):1481. 3.
51. Stoeckli M., Chaurand P., Hallahan D.E., Caprioli R.M. Imaging mass spectrometry: a new technology for the analysis of protein expression in mammalian tissues. Nat. Med. 2001, 7(4):493-496.
52. Rompp A., Spengler B. Mass spectrometry imaging with high resolution in mass and space. Histochem. Cell Biol. 2013, 139(6):759-783.
53. Norris J.L., Caprioli R.M. Analysis of tissue specimens by matrix-assisted laser desorption/ionization imaging mass spectrometry in biological and clinical research. Chem. Rev. 2013, 113(4):2309-2342.
54. Aichler M., Walch A. MALDI Imaging mass spectrometry: current frontiers and perspectives in pathology research and practice. Lab. Invest. 2015, 95(4):422-431.
55. Balluff B., Frese C.K., Maier S.K., Schone C., Kuster B., Schmitt M., et al. De novo discovery of phenotypic intratumour heterogeneity using imaging mass spectrometry. J. Pathol. 2015, 235(1):3-13.
56. Buck A., Halbritter S., Spath C., Feuchtinger A., Aichler M., Zitzelsberger H., et al. Distribution and quantification of irinotecan and its active metabolite SN-38 in colon cancer murine model systems using MALDI MSI. Anal. Bioanal. Chem. 2015, 407(8):2107-2116.
57. Smith M.J., Culhane A.C., Donovan M., Coffey J.C., Barry B.D., Kelly M.A., et al. Analysis of differential gene expression in colorectal cancer and stroma using fluorescence-activated cell sorting purification. Br. J. Cancer 2009, 100(9):1452-1464.
58. Harbeck N., Schwarze S., Schuren E., Yamamoto N., Moniwa N., Schmitt M., et al. Model system for isolation of competent ovarian-carcinoma cells from fresh tumor-tissue by a magnetic separation technique (MACS). Int. J. Oncol. 1995, 6(6):1249-1254.
59. Ibrahim S.F., van den Engh G. High-speed cell sorting: fundamentals and recent advances. Curr. Opin. Biotechnol. 2003, 14(1):5-12.
60. Tomlinson M.J., Tomlinson S., Yang X.B., Kirkham J. Cell separation: terminology and practical considerations. J. Tissue Eng. 2013, 4. 2041731412472690.
61. Chen P., Feng X., Du W., Liu B.F. Microfluidic chips for cell sorting. Front. Biosci. 2008, 13:2464-2483.
62. Chatenoud L., Bluestone J.A. CD3-specific antibodies: a portal to the treatment of autoimmunity. Nat. Rev. Immunol. 2007, 7(8):622-632.
63. Gossett D.R., Weaver W.M., Mach A.J., Hur S.C., Tse H.T., Lee W., et al. Label-free cell separation and sorting in microfluidic systems. Anal. Bioanal. Chem. 2010, 397(8):3249-3267.
64. Laiho K., Penttila A. Autolytic changes in blood cells and other tissue cells of human cadavers. I. Viability and ion studies. Forensic Sci. Int. 1981, 17(2):109-120.
65. D'Armini A.M., Tom E.J., Roberts C.S., Henke D.C., Lemasters J.J., Egan T.M. When does the lung die? Time course of high energy phosphate depletion and relationship to lung viability after "death". J. Surg. Res. 1995, 59(4):468-474.
66. Hanahan D., Weinberg R.A. Hallmarks of cancer: the next generation. Cell 2011, 144(5):646-674.
67. Winslow S., Leandersson K., Edsjo A., Larsson C. Prognostic stromal gene signatures in breast cancer. Breast Cancer Res. 2015, 17:23.
68. Busuttil R.A., George J., Tothill R.W., Ioculano K., Kowalczyk A., Mitchell C., et al. A signature predicting poor prognosis in gastric and ovarian cancer represents a coordinated macrophage and stromal response. Clin. Cancer Res. 2014, 20(10):2761-2772.
69. Jia Z., Rahmatpanah F.B., Chen X., Lernhardt W., Wang Y., Xia X.Q., et al. Expression changes in the stroma of prostate cancer predict subsequent relapse. PLOS ONE 2012, 7(8):e41371.
70. Calon A., Lonardo E., Berenguer-Llergo A., Espinet E., Hernando-Momblona X., Iglesias M., et al. Stromal gene expression defines poor-prognosis subtypes in colorectal cancer. Nat. Genet. 2015, 47(4):320-329.
71. Isella C., Terrasi A., Bellomo S.E., Petti C., Galatola G., Muratore A., et al. Stromal contribution to the colorectal cancer transcriptome. Nat. Genet. 2015.
72. De Sousa E.M.F., Wang X., Jansen M., Fessler E., Trinh A., de Rooij L.P., et al. Poor-prognosis colon cancer is defined by a molecularly distinct subtype and develops from serrated precursor lesions. Nat. Med. 2013, 19(5):614-618.
73. Sadanandam A., Lyssiotis C.A., Homicsko K., Collisson E.A., Gibb W.J., Wullschleger S., et al. A colorectal cancer classification system that associates cellular phenotype and responses to therapy. Nat. Med. 2013, 19(5):619-625.
74. Marisa L., de Reynies A., Duval A., Selves J., Gaub M.P., Vescovo L., et al. Gene expression classification of colon cancer into molecular subtypes: characterization, validation, and prognostic value. PLoS Med. 2013, 10(5):e1001453.
75. Yu B., Chen X., Li J., Qu Y., Su L., Peng Y., et al. Stromal fibroblasts in the microenvironment of gastric carcinomas promote tumor metastasis via upregulating TAGLN expression. BMC Cell Biol. 2013, 14:17.
76. Underwood T.J., Hayden A.L., Derouet M., Garcia E., Noble F., White M.J., et al. Cancer-associated fibroblasts predict poor outcome and promote periostin-dependent invasion in oesophageal adenocarcinoma. J. Pathol. 2015, 235(3):466-477.
77. Fertig E.J., Lee E., Pandey N.B., Popel A.S. Analysis of gene expression of secreted factors associated with breast cancer metastases in breast cancer subtypes. Sci. Rep. 2015, 5:12133.
78. Patel S., Ngounou Wetie A.G., Darie C.C., Clarkson B.D. Cancer secretomes and their place in supplementing other hallmarks of cancer. Adv. Exp. Med. Biol. 2014, 806:409-442.
79. Dolznig H., Rupp C., Puri C., Haslinger C., Schweifer N., Wieser E., et al. Modeling colon adenocarcinomas in vitro a 3D co-culture system induces cancer-relevant pathways upon tumor cell and stromal fibroblast interaction. Am. J. Pathol. 2011, 179(1):487-501.
80. Rudisch A., Dewhurst M.R., Horga L.G., Kramer N., Harrer N., Dong M., et al. High EMT Signature Score of Invasive Non-Small Cell Lung Cancer (NSCLC) Cells Correlates with NFkappaB Driven Colony-Stimulating Factor 2 (CSF2/GM-CSF) Secretion by Neighboring Stromal Fibroblasts. PLOS ONE 2015, 10(4):e0124283.
81. Decaudin D. Primary human tumor xenografted models ('tumorgrafts') for good management of patients with cancer. Anticancer Drugs 2011, 22(9):827-841.
82. Rongvaux A., Takizawa H., Strowig T., Willinger T., Eynon E.E., Flavell R.A., et al. Human hemato-lymphoid system mice: current use and future potential for medicine. Annu. Rev. Immunol. 2013, 31:635-674.
83. Holzapfel B.M., Thibaudeau L., Hesami P., Taubenberger A., Holzapfel N.P., Mayer-Wagner S., et al. Humanised xenograft models of bone metastasis revisited: novel insights into species-specific mechanisms of cancer cell osteotropism. Cancer Metastasis Rev. 2013, 32(1-2):129-145.
84. Hirschhaeuser F., Menne H., Dittfeld C., West J., Mueller-Klieser W., Kunz-Schughart L.A. Multicellular tumor spheroids: an underestimated tool is catching up again. J. Biotechnol. 2010.
85. Frieboes H.B., Zheng X., Sun C.H., Tromberg B., Gatenby R., Cristini V. An integrated computational/experimental model of tumor invasion. Cancer Res. 2006, 66(3):1597-1604.
86. Yamada K.M., Cukierman E. Modeling tissue morphogenesis and cancer in 3D. Cell 2007, 130(4):601-610.
87. Thoma C.R., Zimmermann M., Agarkova I., Kelm J.M., Krek W. 3D cell culture systems modeling tumor growth determinants in cancer target discovery. Adv. Drug Deliv. Rev. 2014, 69-70C:29-41.
88. Weiswald L.B., Bellet D., Dangles-Marie V. Spherical cancer models in tumor biology. Neoplasia 2015, 17(1):1-15.
89. Harrison R. Observations on the living developing nerve fiber. Proc. Soc. Exp. Biol. Med. 1907, 4:140-143.
90. Kelm J.M., Timmins N.E., Brown C.J., Fussenegger M., Nielsen L.K. Method for generation of homogeneous multicellular tumor spheroids applicable to a wide variety of cell types. Biotechnol. Bioeng. 2003, 83(2):173-180.
91. Neto A.I., Correia C.R., Oliveira M.B., Rial-Hermida M.I., Alvarez-Lorenzo C., Reis R.L., et al. A novel hanging spherical drop system for the generation of cellular spheroids and high throughput combinatorial drug screening. Biomater. Sci. 2015, 3(4):581-585.
92. Yuhas J.M., Li A.P., Martinez A.O., Ladman A.J. A simplified method for production and growth of multicellular tumor spheroids. Cancer Res. 1977, 37(10):3639-3643.
93. Carlsson J., Yuhas J.M. Liquid-overlay culture of cellular spheroids. Recent Results Cancer Res. 1984, 95:1-23.
94. Dangles V., Femenia F., Laine V., Berthelemy M., Le Rhun D., Poupon M.F., et al. Two- and three-dimensional cell structures govern epidermal growth factor survival function in human bladder carcinoma cell lines. Cancer Res. 1997, 57(16):3360-3364.
95. Leung B.M., Lesher-Perez S.C., Matsuoka T., Moraes C., Takayama S. Media additives to promote spheroid circularity and compactness in hanging drop platform. Biomater. Sci. 2015, 3(2):336-344.
96. Longati P., Jia X., Eimer J., Wagman A., Witt M.R., Rehnmark S., et al. 3D pancreatic carcinoma spheroids induce a matrix-rich, chemoresistant phenotype offering a better model for drug testing. BMC Cancer 2013, 13:95.
97. Vinci M., Gowan S., Boxall F., Patterson L., Zimmermann M., Court W., et al. Advances in establishment and analysis of three-dimensional tumor spheroid-based functional assays for target validation and drug evaluation. BMC Biol. 2012, 10:29.
98. Tsunoda T., Ishikura S., Doi K., Iwaihara Y., Hidesima H., Luo H., et al. Establishment of a three-dimensional floating cell culture system for screening drugs targeting KRAS-mediated signaling molecules. Anticancer Res. 2015, 35(8):4453-4459.
99. Schon B.S., Schrobback K., van der Ven M., Stroebel S., Hooper G.J., Woodfield T.B. Validation of a high-throughput microtissue fabrication process for 3D assembly of tissue engineered cartilage constructs. Cell Tissue Res. 2012.
100. Sutherland R.M., McCredie J.A., Inch W.R. Growth of multicell spheroids in tissue culture as a model of nodular carcinomas. J. Natl. Cancer Inst. 1971, 46(1):113-120.
101. Rodday B., Hirschhaeuser F., Walenta S., Mueller-Klieser W. Semiautomatic growth analysis of multicellular tumor spheroids. J. Biomol. Screen. 2011, 16(9):1119-1124.
102. Baron M.G., Purcell W.M., Jackson S.K., Owen S.F., Jha A.N. Towards a more representative in vitro method for fish ecotoxicology: morphological and biochemical characterisation of three-dimensional spheroidal hepatocytes. Ecotoxicology 2012, 21(8):2419-2429.
103. Abeille F., Mittler F., Obeid P., Huet M., Kermarrec F., Dolega M.E., et al. Continuous microcarrier-based cell culture in a benchtop microfluidic bioreactor. Lab Chip 2014, 14(18):3510-3518.
104. Goldshmid R., Mironi-Harpaz I., Shachaf Y., Seliktar D. A method for preparation of hydrogel microcapsules for stem cell bioprocessing and stem cell therapy. Methods 2015, 84:35-43.
105. Gong X., Lin C., Cheng J., Su J., Zhao H., Liu T., et al. Generation of multicellular tumor spheroids with microwell-based agarose scaffolds for drug testing. PLOS ONE 2015, 10(6):e0130348.
106. Rivron N.C., Rouwkema J., Truckenmuller R., Karperien M., De Boer J., Van Blitterswijk C.A. Tissue assembly and organization: developmental mechanisms in microfabricated tissues. Biomaterials 2009, 30(28):4851-4858.
107. Huang Y.J., Hsu S.H. Acquisition of epithelial-mesenchymal transition and cancer stem-like phenotypes within chitosan-hyaluronan membrane-derived 3D tumor spheroids. Biomaterials 2014, 35(38):10070-10079.
108. Barrera-Rodriguez R., Fuentes J.M. Multidrug resistance characterization in multicellular tumour spheroids from two human lung cancer cell lines. Cancer Cell Int. 2015, 15:47.
109. Durand R.E., Sutherland R.M. Effects of intercellular contact on repair of radiation damage. Exp. Cell Res. 1972, 71(1):75-80.
110. West C.M., Sutherland R.M. The radiation response of a human colon adenocarcinoma grown in monolayer, as spheroids, and in nude mice. Radiat. Res. 1987, 112(1):105-115.
111. Desoize B., Gimonet D., Jardillier J.C. Multicellular resistance: another mechanism for multidrug resistance?. Bull. Cancer 1998, 85(9):785.
112. Walzl A., Unger C., Kramer N., Unterleuthner D., Scherzer M., Hengstschlager M., et al. The resazurin reduction assay can distinguish cytotoxic from cytostatic compounds in spheroid screening assays. J. Biomol. Screen. 2014.
113. Wenzel C., Riefke B., Grundemann S., Krebs A., Christian S., Prinz F., et al. 3D high-content screening for the identification of compounds that target cells in dormant tumor spheroid regions. Exp. Cell Res. 2014, 323(1):131-143.
114. Blangy A., Lane H.A., d'Herin P., Harper M., Kress M., Nigg E.A. Phosphorylation by p34cdc2 regulates spindle association of human Eg5, a kinesin-related motor essential for bipolar spindle formation in vivo. Cell 1995, 83(7):1159-1169.
115. Thoma C.R., Stroebel S., Rosch N., Calpe B., Krek W., Kelm J.M. A high-throughput-compatible 3D microtissue co-culture system for phenotypic RNAi screening applications. J. Biomol. Screen. 2013, 18(10):1330-1337.
116. Dolznig H., Walzl A., Kramer N., Rosner M., Garin-Chesa P., Hengstschlager M. Organotypic spheroid cultures to study tumor-stroma interaction during cancer development. Drug Discov. Today Dis. Models 2011, 8(2-3):113-119.
117. Hoffmann T.K., Schirlau K., Sonkoly E., Brandau S., Lang S., Pivarcsi A., et al. A novel mechanism for anti-EGFR antibody action involves chemokine-mediated leukocyte infiltration. Int. J. Cancer 2009, 124(11):2589-2596.
118. Graves D.T., Valente A.J. Monocyte chemotactic proteins from human tumor cells. Biochem. Pharmacol. 1991, 41(3):333-337.
119. Lee J.A., Berg E.L. Neoclassic drug discovery: the case for lead generation using phenotypic and functional approaches. J. Biomol. Screen. 2013, 18(10):1143-1155.
120. Reynolds B.A., Weiss S. Generation of neurons and astrocytes from isolated cells of the adult mammalian central nervous system. Science 1992, 255(5052):1707-1710.
121. Chen H.C., Lee J.T., Shih C.P., Chao T.T., Sytwu H.K., Li S.L., et al. Hypoxia induces a metabolic shift and enhances the stemness and expansion of cochlear spiral ganglion stem/progenitor cells. Biomed. Res. Int. 2015, 2015:359537.
122. Karthik G.M., Ma R., Lovrot J., Kis L.L., Lindh C., Blomquist L., et al. mTOR inhibitors counteract tamoxifen-induced activation of breast cancer stem cells. Cancer Lett. 2015, 367(1):76-87.
123. He M., Fu Y., Yan Y., Xiao Q., Wu H., Yao W., et al. The Hedgehog signalling pathway mediates drug response of MCF-7 mammosphere cells in breast cancer patients. Clin. Sci. 2015, 129(9):809-822.
124. Ricci-Vitiani L., Lombardi D.G., Pilozzi E., Biffoni M., Todaro M., Peschle C., et al. Identification and expansion of human colon-cancer-initiating cells. Nature 2007, 445(7123):111-115.
125. Cristobal I., Rincon R., Manso R., Carames C., Zazo S., Madoz-Gurpide J., et al. Deregulation of the PP2A inhibitor SET shows promising therapeutic implications and determines poor clinical outcome in patients with metastatic colorectal cancer. Clin. Cancer Res. 2015, 21(2):347-356.
126. Visvader J.E., Lindeman G.J. Cancer stem cells in solid tumours: accumulating evidence and unresolved questions. Nat. Rev. Cancer 2008, 8(10):755-768.
127. Valverde A., Penarando J., Canas A., Lopez-Sanchez L.M., Conde F., Hernandez V., et al. Simultaneous inhibition of EGFR/VEGFR and cyclooxygenase-2 targets stemness-related pathways in colorectal cancer cells. PLOS ONE 2015, 10(6):e0131363.
128. Kondo J., Endo H., Okuyama H., Ishikawa O., Iishi H., Tsujii M., et al. Retaining cell-cell contact enables preparation and culture of spheroids composed of pure primary cancer cells from colorectal cancer. Proc. Natl. Acad. Sci. U.S.A. 2011, 108(15):6235-6240.
129. Okuyama H., Yoshida T., Endo H., Nakayama M., Nonomura N., Nishimura K., et al. Involvement of heregulin/HER3 in the primary culture of human urothelial cancer. J. Urol. 2013, 190(1):302-310.
130. Nakajima A., Endo H., Okuyama H., Kiyohara Y., Kimura T., Kamiura S., et al. Radiation sensitivity assay with a panel of patient-derived spheroids of small cell carcinoma of the cervix. Int. J. Cancer 2015, 136(12):2949-2960.
131. Yoshida T., Okuyama H., Nakayama M., Endo H., Nonomura N., Nishimura K., et al. High-dose chemotherapeutics of intravesical chemotherapy rapidly induce mitochondrial dysfunction in bladder cancer-derived spheroids. Cancer Sci. 2015, 106(1):69-77.
132. Bjerkvig R., Tonnesen A., Laerum O.D., Backlund E.O. Multicellular tumor spheroids from human gliomas maintained in organ culture. J. Neurosurg. 1990, 72(3):463-475.
133. Sundlisaeter E., Wang J., Sakariassen P.O., Marie M., Mathisen J.R., Karlsen B.O., et al. Primary glioma spheroids maintain tumourogenicity and essential phenotypic traits after cryopreservation. Neuropathol. Appl. Neurobiol. 2006, 32(4):419-427.
134. Mahesparan R., Tysnes B.B., Read T.A., Enger P.O., Bjerkvig R., Lund-Johansen M. Extracellular matrix-induced cell migration from glioblastoma biopsy specimens in vitro. Acta Neuropathol. 1999, 97(3):231-239.
135. Aaberg-Jessen C., Norregaard A., Christensen K., Pedersen C.B., Andersen C., Kristensen B.W. Invasion of primary glioma- and cell line-derived spheroids implanted into corticostriatal slice cultures. Int. J. Clin. Exp. Pathol. 2013, 6(4):546-560.
136. Fjellbirkeland L., Bjerkvig R., Laerum O.D. Tumour fragment spheroids from human non-small-cell lung cancer maintained in organ culture. Virchows Arch. 1995, 426(2):169-178.
137. Barbone D., Cheung P., Battula S., Busacca S., Gray S.G., Longley D.B., et al. Vorinostat eliminates multicellular resistance of mesothelioma 3D spheroids via restoration of Noxa expression. PLOS ONE 2012, 7(12):e52753.
138. Worthington P., Pochan D.J., Langhans S.A. Peptide hydrogels - versatile matrices for 3D cell culture in cancer medicine. Front. Oncol. 2015, 5:92.
139. Hutmacher D.W., Loessner D., Rizzi S., Kaplan D.L., Mooney D.J., Clements J.A. Can tissue engineering concepts advance tumor biology research?. Trends Biotechnol. 2010, 28(3):125-133.
140. Chan H.F., Zhang Y., Ho Y.P., Chiu Y.L., Jung Y., Leong K.W. Rapid formation of multicellular spheroids in double-emulsion droplets with controllable microenvironment. Sci. Rep. 2013, 3:3462.
141. Papas K.K., Long R.C., Sambanis A., Constantinidis I. Development of a bioartificial pancreas. I. Long-term propagation and basal and induced secretion from entrapped betaTC3 cell cultures. Biotechnol. Bioeng. 1999, 66(4):219-230.
142. Kolambkar Y.M., Boerckel J.D., Dupont K.M., Bajin M., Huebsch N., Mooney D.J., et al. Spatiotemporal delivery of bone morphogenetic protein enhances functional repair of segmental bone defects. Bone 2011, 49(3):485-492.
143. Venkatesan J., Bhatnagar I., Manivasagan P., Kang K.H., Kim S.K. Alginate composites for bone tissue engineering: a review. Int. J. Biol. Macromol. 2014.
144. Rao W., Zhao S., Yu J., Lu X., Zynger D.L., He X. Enhanced enrichment of prostate cancer stem-like cells with miniaturized 3D culture in liquid core-hydrogel shell microcapsules. Biomaterials 2014, 35(27):7762-7773.
145. Sakai S., Inamoto K., Ashida T., Takamura R., Taya M. Cancer stem cell marker-expressing cell-rich spheroid fabrication from PANC-1 cells using alginate microcapsules with spherical cavities templated by gelatin microparticles. Biotechnol. Prog. 2015, 31(4):1071-1076.
146. Rowley J.A., Madlambayan G., Mooney D.J. Alginate hydrogels as synthetic extracellular matrix materials. Biomaterials 1999, 20(1):45-53.
147. Fischbach C., Kong H.J., Hsiong S.X., Evangelista M.B., Yuen W., Mooney D.J. Cancer cell angiogenic capability is regulated by 3D culture and integrin engagement. Proc. Natl. Acad. Sci. U.S.A. 2009, 106(2):399-404.
148. Branco da Cunha C., Klumpers D.D., Li W.A., Koshy S.T., Weaver J.C., Chaudhuri O., et al. Influence of the stiffness of three-dimensional alginate/collagen-I interpenetrating networks on fibroblast biology. Biomaterials 2014, 35(32):8927-8936.
149. Chaudhuri O., Koshy S.T., Branco da Cunha C., Shin J.W., Verbeke C.S., Allison K.H., et al. Extracellular matrix stiffness and composition jointly regulate the induction of malignant phenotypes in mammary epithelium. Nat. Mater. 2014.
150. Andersen T., Markussen C., Dornish M., Heier-Baardson H., Melvik J.E., Alsberg E., et al. In situ gelation for cell immobilization and culture in alginate foam scaffolds. Tissue Eng. A 2014, 20(3-4):600-610.
151. Godugu C., Patel A.R., Desai U., Andey T., Sams A., Singh M. AlgiMatrix based 3D cell culture system as an in-vitro tumor model for anticancer studies. PLOS ONE 2013, 8(1):e53708.
152. Lee D.W., Choi Y.S., Seo Y.J., Lee M.Y., Jeon S.Y., Ku B., et al. High-throughput screening (HTS) of anticancer drug efficacy on a micropillar/microwell chip platform. Anal. Chem. 2014, 86(1):535-542.
153. Barker N., van Es J.H., Kuipers J., Kujala P., van den Born M., Cozijnsen M., et al. Identification of stem cells in small intestine and colon by marker gene Lgr5. Nature 2007, 449(7165):1003-1007.
154. Sato T., Vries R.G., Snippert H.J., van de Wetering M., Barker N., Stange D.E., et al. Single Lgr5 stem cells build crypt-villus structures in vitro without a mesenchymal niche. Nature 2009, 459(7244):262-265.
155. Sato T., Stange D.E., Ferrante M., Vries R.G., Van Es J.H., Van den Brink S., et al. Long-term expansion of epithelial organoids from human colon, adenoma, adenocarcinoma, and Barrett's epithelium. Gastroenterology 2011, 141(5):1762-1772.
156. Hirokawa Y., Yip K.H., Tan C.W., Burgess A.W. Colonic myofibroblast cell line stimulates colonoid formation. Am. J. Physiol. Gastrointest. Liver Physiol. 2014, 306(7):G547-G556.
157. Prasetyanti P.R., Zimberlin C.D., Bots M., Vermeulen L., Melo Fde S., Medema J.P. Regulation of stem cell self-renewal and differentiation by Wnt and Notch are conserved throughout the adenoma-carcinoma sequence in the colon. Mol. Cancer 2013, 12(1):126.
158. Dontu G., Abdallah W.M., Foley J.M., Jackson K.W., Clarke M.F., Kawamura M.J., et al. In vitro propagation and transcriptional profiling of human mammary stem/progenitor cells. Genes Dev. 2003, 17(10):1253-1270.
159. Rock J.R., Onaitis M.W., Rawlins E.L., Lu Y., Clark C.P., Xue Y., et al. Basal cells as stem cells of the mouse trachea and human airway epithelium. Proc. Natl. Acad. Sci. U.S.A. 2009, 106(31):12771-12775.
160. Barker N., Huch M., Kujala P., van de Wetering M., Snippert H.J., van Es J.H., et al. Lgr5(+ve) stem cells drive self-renewal in the stomach and build long-lived gastric units in vitro. Cell Stem Cell 2010, 6(1):25-36.
161. Lukacs R.U., Goldstein A.S., Lawson D.A., Cheng D., Witte O.N. Isolation, cultivation and characterization of adult murine prostate stem cells. Nat. Protoc. 2010, 5(4):702-713.
162. Astashkina A.I., Mann B.K., Prestwich G.D., Grainger D.W. A 3-D organoid kidney culture model engineered for high-throughput nephrotoxicity assays. Biomaterials 2012, 33(18):4700-4711.
163. Greggio C., De Franceschi F., Figueiredo-Larsen M., Gobaa S., Ranga A., Semb H., et al. Artificial three-dimensional niches deconstruct pancreas development in vitro. Development 2013, 140(21):4452-4462.
164. Huch M., Dorrell C., Boj S.F., van Es J.H., Li V.S., van de Wetering M., et al. In vitro expansion of single Lgr5+ liver stem cells induced by Wnt-driven regeneration. Nature 2013, 494(7436):247-250.
165. van de Wetering M., Francies H.E., Francis J.M., Bounova G., Iorio F., Pronk A., et al. Prospective derivation of a living organoid biobank of colorectal cancer patients. Cell 2015, 161(4):933-945.
166. Ranga A., Gjorevski N., Lutolf M.P. Drug discovery through stem cell-based organoid models. Adv. Drug Deliv. Rev. 2014, 69-70C:19-28.
167. Sachs N., Clevers H. Organoid cultures for the analysis of cancer phenotypes. Curr. Opin. Genet. Dev. 2014, 24:68-73.
168. Kenny P.A. Three-dimensional extracellular matrix culture models of EGFR signalling and drug response. Biochem. Soc. Trans. 2007, 35(Pt 4):665-668.
169. Lee J.M., Mhawech-Fauceglia P., Lee N., Parsanian L.C., Lin Y.G., Gayther S.A., et al. A three-dimensional microenvironment alters protein expression and chemosensitivity of epithelial ovarian cancer cells in vitro. Lab. Invest. 2013, 93(5):528-542.
170. Rintoul R.C., Sethi T. Extracellular matrix regulation of drug resistance in small-cell lung cancer. Clin. Sci. 2002, 102(4):417-424.
171. Lee G.Y., Kenny P.A., Lee E.H., Bissell M.J. Three-dimensional culture models of normal and malignant breast epithelial cells. Nat. Methods 2007, 4(4):359-365.
172. Yip D., Cho C.H. A multicellular 3D heterospheroid model of liver tumor and stromal cells in collagen gel for anti-cancer drug testing. Biochem. Biophys. Res. Commun. 2013, 433(3):327-332.
173. Gaggioli C., Hooper S., Hidalgo-Carcedo C., Grosse R., Marshall J.F., Harrington K., et al. Fibroblast-led collective invasion of carcinoma cells with differing roles for RhoGTPases in leading and following cells. Nat. Cell Biol. 2007, 9(12):1392-1400.
174. Pickard A., Cichon A.C., Barry A., Kieran D., Patel D., Hamilton P., et al. Inactivation of Rb in stromal fibroblasts promotes epithelial cell invasion. EMBO J. 2012, 31(14):3092-3103.
175. Timpson P., McGhee E.J., Erami Z., Nobis M., Quinn J.A., Edward M., et al. Organotypic collagen I assay: a malleable platform to assess cell behaviour in a 3-dimensional context. J. Vis. Exp. 2011, 56:e3089.
176. Weigelt B., Ghajar C.M., Bissell M.J. The need for complex 3D culture models to unravel novel pathways and identify accurate biomarkers in breast cancer. Adv. Drug Deliv. Rev. 2014, 69-70C:42-51.
177. Tiago M., de Oliveira E.M., Brohem C.A., Pennacchi P.C., Paes R.D., Haga R.B., et al. Fibroblasts protect melanoma cells from the cytotoxic effects of doxorubicin. Tissue Eng. A 2014.
178. Maas-Szabowski N., Szabowski A., Stark H.J., Andrecht S., Kolbus A., Schorpp-Kistner M., et al. Organotypic cocultures with genetically modified mouse fibroblasts as a tool to dissect molecular mechanisms regulating keratinocyte growth and differentiation. J. Invest. Dermatol. 2001, 116(5):816-820.
179. Froeling F.E., Mirza T.A., Feakins R.M., Seedhar A., Elia G., Hart I.R., et al. Organotypic culture model of pancreatic cancer demonstrates that stromal cells modulate E-cadherin, beta-catenin, and Ezrin expression in tumor cells. Am. J. Pathol. 2009, 175(2):636-648.
180. Okawa T., Michaylira C.Z., Kalabis J., Stairs D.B., Nakagawa H., Andl C.D., et al. The functional interplay between EGFR overexpression, hTERT activation, and p53 mutation in esophageal epithelial cells with activation of stromal fibroblasts induces tumor development, invasion, and differentiation. Genes Dev. 2007, 21(21):2788-2803.
181. van Zijl F., Mair M., Csiszar A., Schneller D., Zulehner G., Huber H., et al. Hepatic tumor-stroma crosstalk guides epithelial to mesenchymal transition at the tumor edge. Oncogene 2009.
182. Nystrom M.L., Thomas G.J., Stone M., Mackenzie I.C., Hart I.R., Marshall J.F. Development of a quantitative method to analyse tumour cell invasion in organotypic culture. J. Pathol. 2005, 205(4):468-475.
183. Seano G., Chiaverina G., Gagliardi P.A., di Blasio L., Sessa R., Bussolino F., et al. Modeling human tumor angiogenesis in a three-dimensional culture system. Blood 2013, 121(21):e129-e137.
184. Ghajar C.M., Peinado H., Mori H., Matei I.R., Evason K.J., Brazier H., et al. The perivascular niche regulates breast tumour dormancy. Nat. Cell Biol. 2013, 15(7):807-817.
185. Bechetoille N., Vachon H., Gaydon A., Boher A., Fontaine T., Schaeffer E., et al. A new organotypic model containing dermal-type macrophages. Exp. Dermatol. 2011, 20(12):1035-1037.
186. Linde N., Gutschalk C.M., Hoffmann C., Yilmaz D., Mueller M.M. Integrating macrophages into organotypic co-cultures: a 3D in vitro model to study tumor-associated macrophages. PLOS ONE 2012, 7(7):e40058.
187. Mathes S.H., Ruffner H., Graf-Hausner U. The use of skin models in drug development. Adv. Drug Deliv. Rev. 2014, 69-70C:81-102.
188. Ridky T.W., Chow J.M., Wong D.J., Khavari P.A. Invasive three-dimensional organotypic neoplasia from multiple normal human epithelia. Nat. Med. 2010, 16(12):1450-1455.
189. Pickard A., McDade S.S., McFarland M., McCluggage W.G., Wheeler C.M., McCance D.J. HPV16 down-regulates the insulin-like growth factor binding protein 2 to promote epithelial invasion in organotypic cultures. PLoS Pathog. 2015, 11(6):e1004988.
190. Westcott J.M., Prechtl A.M., Maine E.A., Dang T.T., Esparza M.A., Sun H., et al. An epigenetically distinct breast cancer cell subpopulation promotes collective invasion. J. Clin. Invest. 2015, 125(5):1927-1943.
191. Kenny H.A., Lal-Nag M., White E.A., Shen M., Chiang C.Y., Mitra A.K., et al. Quantitative high throughput screening using a primary human three-dimensional organotypic culture predicts in vivo efficacy. Nat. Commun. 2015, 6:6220.
192. Nobis M., McGhee E.J., Morton J.P., Schwarz J.P., Karim S.A., Quinn J., et al. Intravital FLIM-FRET imaging reveals dasatinib-induced spatial control of SRC in pancreatic cancer. Cancer Res. 2013, 73(15):4674-4686.
193. Ren X., Tapias L.F., Jank B.J., Mathisen D.J., Lanuti M., Ott H.C. Ex vivo non-invasive assessment of cell viability and proliferation in bio-engineered whole organ constructs. Biomaterials 2015, 52:103-112.
194. Moser P.T., Ott H.C. Recellularization of organs: what is the future for solid organ transplantation?. Curr. Opin. Organ Transplant. 2014, 19(6):603-609.
195. Scarritt M.E., Pashos N.C., Bunnell B.A. A review of cellularization strategies for tissue engineering of whole organs. Front. Bioeng. Biotechnol. 2015, 3:43.
196. O'Neill J.D., Anfang R., Anandappa A., Costa J., Javidfar J., Wobma H.M., et al. Decellularization of human and porcine lung tissues for pulmonary tissue engineering. Ann. Thorac. Surg. 2013, 96(3):1046-1055. discussion 55-56.
197. Song J.J., Guyette J.P., Gilpin S.E., Gonzalez G., Vacanti J.P., Ott H.C. Regeneration and experimental orthotopic transplantation of a bioengineered kidney. Nat. Med. 2013, 19(5):646-651.
198. Uygun B.E., Soto-Gutierrez A., Yagi H., Izamis M.L., Guzzardi M.A., Shulman C., et al. Organ reengineering through development of a transplantable recellularized liver graft using decellularized liver matrix. Nat. Med. 2010, 16(7):814-820.
199. Ott H.C., Matthiesen T.S., Goh S.K., Black L.D., Kren S.M., Netoff T.I., et al. Perfusion-decellularized matrix: using nature's platform to engineer a bioartificial heart. Nat. Med. 2008, 14(2):213-221.
200. Schanz J., Pusch J., Hansmann J., Walles H. Vascularised human tissue models: a new approach for the refinement of biomedical research. J. Biotechnol. 2010, 148(1):56-63.
201. Hussein K.H., Park K.M., Ghim J.H., Yang S.R., Woo H.M. Three dimensional culture of HepG2 liver cells on a rat decellularized liver matrix for pharmacological studies. J. Biomed. Mater. Res. B: Appl. Biomater. 2015.
202. Stratmann A.T., Fecher D., Wangorsch G., Gottlich C., Walles T., Walles H., et al. Establishment of a human 3D lung cancer model based on a biological tissue matrix combined with a Boolean in silico model. Mol. Oncol. 2014, 8(2):351-365.
203. Tapias L.F., Gilpin S.E., Ren X., Wei L., Fuchs B.C., Tanabe K.K., et al. Assessment of proliferation and cytotoxicity in a biomimetic three-dimensional model of lung cancer. Ann. Thorac. Surg. 2015, 100(2):414-421.
204. Fields R.D., Lancaster M.V. Dual-attribute continuous monitoring of cell-proliferation cytotoxicity. Am. Biotechnol. Lab. 1993, 11(4):48-50.
205. Thiery J.P. Epithelial-mesenchymal transitions in tumour progression. Nat. Rev. Cancer 2002, 2(6):442-454.
206. Reymond N., d'Agua B.B., Ridley A.J. Crossing the endothelial barrier during metastasis. Nat. Rev. Cancer 2013, 13(12):858-870.
207. Pantel K., Speicher M.R. The biology of circulating tumor cells. Oncogene 2015.
208. Jeon J.S., Zervantonakis I.K., Chung S., Kamm R.D., Charest J.L. In vitro model of tumor cell extravasation. PLOS ONE 2013, 8(2):e56910.
209. Joyce J.A., Pollard J.W. Microenvironmental regulation of metastasis. Nat. Rev. Cancer 2009, 9(4):239-252.
210. Stoletov K., Kato H., Zardouzian E., Kelber J., Yang J., Shattil S., et al. Visualizing extravasation dynamics of metastatic tumor cells. J. Cell Sci. 2010, 123(Pt 13):2332-2341.
211. Kerjaschki D., Bago-Horvath Z., Rudas M., Sexl V., Schneckenleithner C., Wolbank S., et al. Lipoxygenase mediates invasion of intrametastatic lymphatic vessels and propagates lymph node metastasis of human mammary carcinoma xenografts in mouse. J. Clin. Invest. 2011, 121(5):2000-2012.
212. Vonach C., Viola K., Giessrigl B., Huttary N., Raab I., Kalt R., et al. NF-kappaB mediates the 12(S)-HETE-induced endothelial to mesenchymal transition of lymphendothelial cells during the intravasation of breast carcinoma cells. Br. J. Cancer 2011, 105(2):263-271.
213. Viola K., Kopf S., Huttary N., Vonach C., Kretschy N., Teichmann M., et al. Bay11-7082 inhibits the disintegration of the lymphendothelial barrier triggered by MCF-7 breast cancer spheroids; the role of ICAM-1 and adhesion. Br. J. Cancer 2013, 108(3):564-569.
214. Senfter D., Holzner S., Kalipciyan M., Staribacher A., Walzl A., Huttary N., et al. Loss of miR-200 family in 5-fluorouracil resistant colon cancer drives lymphendothelial invasiveness in vitro. Hum. Mol. Genet. 2015, 24(13):3689-3698.
215. Kopf S., Viola K., Atanasov A.G., Jarukamjorn K., Rarova L., Kretschy N., et al. In vitro characterisation of the anti-intravasative properties of the marine product heteronemin. Arch. Toxicol. 2013, 87(10):1851-1861.
216. Viola K., Kopf S., Rarova L., Jarukamjorn K., Kretschy N., Teichmann M., et al. Xanthohumol attenuates tumour cell-mediated breaching of the lymphendothelial barrier and prevents intravasation and metastasis. Arch. Toxicol. 2013, 87(7):1301-1312.
217. Giessrigl B., Yazici G., Teichmann M., Kopf S., Ghassemi S., Atanasov A.G., et al. Effects of Scrophularia extracts on tumor cell proliferation, death and intravasation through lymphoendothelial cell barriers. Int. J. Oncol. 2012, 40(6):2063-2074.
218. Kretschy N., Teichmann M., Kopf S., Atanasov A.G., Saiko P., Vonach C., et al. In vitro inhibition of breast cancer spheroid-induced lymphendothelial defects resembling intravasation into the lymphatic vasculature by acetohexamide, isoxsuprine, nifedipin and proadifen. Br. J. Cancer 2013, 108(3):570-578.
219. Teichmann M., Kretschy N., Kopf S., Jarukamjorn K., Atanasov A.G., Viola K., et al. Inhibition of tumour spheroid-induced prometastatic intravasation gates in the lymph endothelial cell barrier by carbamazepine: drug testing in a 3D model. Arch. Toxicol. 2014, 88(3):691-699.
220. Whitesides G.M. The origins and the future of microfluidics. Nature 2006, 442(7101):368-373.
221. Wlodkowic D., Cooper J.M. Tumors on chips: oncology meets microfluidics. Curr. Opin. Chem. Biol. 2010, 14(5):556-567.
222. van Duinen V., Trietsch S.J., Joore J., Vulto P., Hankemeier T. Microfluidic 3D cell culture: from tools to tissue models. Curr. Opin. Biotechnol. 2015, 35:118-126.
223. Bersini S., Jeon J.S., Moretti M., Kamm R.D. In vitro models of the metastatic cascade: from local invasion to extravasation. Drug Discov. Today 2014, 19(6):735-742.
224. Takayama S., Ostuni E., LeDuc P., Naruse K., Ingber D.E., Whitesides G.M. Subcellular positioning of small molecules. Nature 2001, 411(6841):1016.
225. Sung K.E., Beebe D.J. Microfluidic 3D models of cancer. Adv. Drug Deliv. Rev. 2014, 79-80:68-78.
226. Kovarik M.L., Ornoff D.M., Melvin A.T., Dobes N.C., Wang Y., Dickinson A.J., et al. Micro total analysis systems: fundamental advances and applications in the laboratory, clinic, and field. Anal. Chem. 2013, 85(2):451-472.
227. Huh D., Hamilton G.A., Ingber D.E. From 3D cell culture to organs-on-chips. Trends Cell Biol. 2011, 21(12):745-754.
228. Young E.W. Cells, tissues, and organs on chips: challenges and opportunities for the cancer tumor microenvironment. Integr. Biol. 2013, 5(9):1096-1109.
229. Jang K.J., Mehr A.P., Hamilton G.A., McPartlin L.A., Chung S., Suh K.Y., et al. Human kidney proximal tubule-on-a-chip for drug transport and nephrotoxicity assessment. Integr. Biol. 2013, 5(9):1119-1129.
230. Lee P.J., Hung P.J., Lee L.P. An artificial liver sinusoid with a microfluidic endothelial-like barrier for primary hepatocyte culture. Biotechnol. Bioeng. 2007, 97(5):1340-1346.
231. Huh D., Matthews B.D., Mammoto A., Montoya-Zavala M., Hsin H.Y., Ingber D.E. Reconstituting organ-level lung functions on a chip. Science 2010, 328(5986):1662-1668.
232. Esch M.B., Smith A.S., Prot J.M., Oleaga C., Hickman J.J., Shuler M.L. How multi-organ microdevices can help foster drug development. Adv. Drug Deliv. Rev. 2014, 69-70C:158-169.
233. Chaw K.C., Manimaran M., Tay E.H., Swaminathan S. Multi-step microfluidic device for studying cancer metastasis. Lab Chip 2007, 7(8):1041-1047.
234. Kuo C.T., Chiang C.L., Chang C.H., Liu H.K., Huang G.S., Huang R.Y., et al. Modeling of cancer metastasis and drug resistance via biomimetic nano-cilia and microfluidics. Biomaterials 2014, 35(5):1562-1571.
235. Ma H., Liu T., Qin J., Lin B. Characterization of the interaction between fibroblasts and tumor cells on a microfluidic co-culture device. Electrophoresis 2010, 31(10):1599-1605.
236. Zervantonakis I.K., Hughes-Alford S.K., Charest J.L., Condeelis J.S., Gertler F.B., Kamm R.D. Three dimensional microfluidic model for tumor cell intravasation and endothelial barrier function. Proc. Natl. Acad. Sci. U.S.A. 2012, 109(34):13515-13520.
237. Mattei F., Schiavoni G., De Ninno A., Lucarini V., Sestili P., Sistigu A., et al. A multidisciplinary study using in vivo tumor models and microfluidic cell-on-chip approach to explore the cross-talk between cancer and immune cells. J. Immunotoxicol. 2014.
238. van de Stolpe A., den Toonder J.M. Circulating tumor cells: what is in it for the patient? A vision towards the future. Cancers (Basel) 2014, 6(2):1195-1207.
239. Kwapiszewska K., Michalczuk A., Rybka M., Kwapiszewski R., Brzozka Z. A microfluidic-based platform for tumour spheroid culture, monitoring and drug screening. Lab Chip 2014, 14(12):2096-2104.
240. Haessler U., Teo J.C., Foretay D., Renaud P., Swartz M.A. Migration dynamics of breast cancer cells in a tunable 3D interstitial flow chamber. Integr. Biol. 2012, 4(4):401-409.
241. Choi Y., Hyun E., Seo J., Blundell C., Kim H.C., Lee E., et al. A microengineered pathophysiological model of early-stage breast cancer. Lab Chip 2015, 15(16):3350-3357.
242. Song J.W., Cavnar S.P., Walker A.C., Luker K.E., Gupta M., Tung Y.C., et al. Microfluidic endothelium for studying the intravascular adhesion of metastatic breast cancer cells. PLoS ONE 2009, 4(6):e5756.
243. Zhang Q., Liu T., Qin J. A microfluidic-based device for study of transendothelial invasion of tumor aggregates in realtime. Lab Chip 2012, 12(16):2837-2842.
244. Chen M.B., Whisler J.A., Jeon J.S., Kamm R.D. Mechanisms of tumor cell extravasation in an in vitro microvascular network platform. Integr. Biol. 2013, 5(10):1262-1271.
245. Hsiao A.Y., Torisawa Y.S., Tung Y.C., Sud S., Taichman R.S., Pienta K.J., et al. Microfluidic system for formation of PC-3 prostate cancer co-culture spheroids. Biomaterials 2009, 30(16):3020-3027.
246. Sung J.H., Kam C., Shuler M.L. A microfluidic device for a pharmacokinetic-pharmacodynamic (PK-PD) model on a chip. Lab Chip 2010, 10(4):446-455.
247. Elliott N.T., Yuan F. A microfluidic system for investigation of extravascular transport and cellular uptake of drugs in tumors. Biotechnol. Bioeng. 2012, 109(5):1326-1335.
248. Gleghorn J.P., Pratt E.D., Denning D., Liu H., Bander N.H., Tagawa S.T., et al. Capture of circulating tumor cells from whole blood of prostate cancer patients using geometrically enhanced differential immunocapture (GEDI) and a prostate-specific antibody. Lab Chip 2010, 10(1):27-29.
249. Kirby B.J., Jodari M., Loftus M.S., Gakhar G., Pratt E.D., Chanel-Vos C., et al. Functional characterization of circulating tumor cells with a prostate-cancer-specific microfluidic device. PLOS ONE 2012, 7(4):e35976.